Lannett Co Inc Common Stock (NYSE:LCI):
Lannett Announces Successful Phase III Clinical Trial Results For Proprietary C-TopicalÂ® Product.
The company is now up by 2.13% since yesterday’s close of $21.15.
Company chares are trading at $21.60 a tad under $26.79, the 50 day moving average and which is marginally lower than the 200 day moving average of $26.06. The 50 day moving average moved down $-5.19 whereas the 200 day moving average was down $-4.46 or -17.11%.
The P/E ratio is currently 18.00 and market cap is 796.87M. In the last earnings report the EPS was $1.20 and is expected to be $3.25 for the current year with 36,892,000 shares presently outstanding. Next quarter’s EPS is expected be $0.82 and the next full year EPS is projected to be $3.31.
Brokerage analysts have issued ratings on Lannett Co Inc Common Stock of late. Equity analyst Deutsche Bank starting coverage on LCI with a rating of “Hold”. On March 24 Roth Capital made no change to the company rating of “Buy” and moved down the price target from $30.00 to $27.50.
Equity analyst Canaccord Genuity lowered the price target and downgraded the stock on March 24 cutting the price target from $28.00 to $18.00 and changing the rating from “Buy” to “Sell”. On March 24 the company was downgraded to “Sell” from “Buy” with a current price target of $18.00 in a report from Canaccord Genuity.
March 11 investment analysts at Roth Capital kept the stock rating at “Buy” and lowered the price expectation to $3.00 from $4.00. On February 4 the stock rating was upgraded from “” to “Buy” in an announcement from Craig-Hallum.